EMILY TURNER: Open Payments
NPI 1013329218 · LOWELL, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$707 in 45 payments from 16 companies in 2025. Trend: 2023 $597 · 2024 $552 · 2025 $707
Food & beverage: $707
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $155 |
| Merck Sharp & Dohme LLC | 5 | $82 |
| Novartis Pharmaceuticals Corporation | 5 | $81 |
| PFIZER INC. | 4 | $64 |
| E.R. Squibb & Sons, L.L.C. | 4 | $57 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| Alkermes, Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
Products named: REPATHA, VERQUVO, ELIQUIS, LEQVIO, Kerendia, CAPLYTA, AMVUTTRA, CAMZYOS.
Industry payments across AR — which companies pay providers there.
